 | This article needs to beupdated. Please help update this article to reflect recent events or newly available information.(August 2025) |
 | |
| Clinical data | |
|---|---|
| Other names | NW-3509; NW-3509A |
| Routes of administration | oral |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C16H26N2O2 |
| Molar mass | 278.396 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Evenamide (INNTooltip International Nonproprietary Name) (developmental code namesNW-3509,NW-3509A)[1] is aselectivevoltage-gated sodium channelblocker, including (and not limited to) subtypesNav1.3,Nav1.7, andNav1.8, which is described as anantipsychotic and is under development by Newron Pharmaceuticals as anadd-on therapy for the treatment ofschizophrenia.[2][3][4][5] The drug has shown efficacy inanimal models ofpsychosis,mania,depression, andaggression.[4] It has completedphase Iclinical trials, andphase II clinical trials will be commenced in the third quarter of 2015.[6]
The drug was discovered by Newron Pharmaceuticals SpA, a pharmaceutical company located in Italy[7]
In a randomized study with treatment-resistant schizophrenia patients, evenamide was added to the treatment regimen, with the psychological assessors beingblinded to whether evenamide was taken. 70% of the participants reported a significant lowering of their impairments; and in 25%, schizophrenia went in full remission. A full double-blind phase III study with treatment-resistant schizophrenia patients is in preparation as of January 2023.[8]
The 4 week placebo trial of 2021 to evaluate the safety, tolerability and preliminary evidence of efficacy of evenamide for people with chronic schizophrenia was selected to address patients who are receiving treatment at constant doses of one of the following atypical antipsychotics: aripiprazole, clozapine, quetiapine, olanzapine, paliperidone or risperidone.[9][10]
